Drug intelligence / Profile preview

ABX203

Development stage: Phase 3
Lead developer: Abivax
Modality: Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
Administration: Intranasal, Subcutaneous

Overview

ABX203 is a therapeutic vaccine developed for the treatment of chronic hepatitis B virus (HBV) infection. It is composed of two recombinant proteins from HBV—the surface antigen (HBsAg) and the nucleocapsid (core) antigen (HBcAg). The vaccine is designed to induce both neutralizing antibodies against HBsAg and strong cellular immune responses, mimicking those seen in patients who naturally clear acute HBV infection. ABX203 has been formulated for administration as a nasal spray or subcutaneous injection. Clinical trials have shown that it can sustain viral load suppression for at least six months after cessation of therapy, potentially offering advantages over standard treatments such as nucleos(t)ide analogues and pegylated interferon alpha[5][4][1]. The drug was originally developed by the Center for Genetic Engineering and Biotechnology in Cuba, with further development and commercialization rights licensed to Abivax.

Other names: HeberNasvac

Targets

HBsAg (Hepatitis B surface antigen)HBc (Hepatitis B virus core protein)

Beyond the preview

Go deeper on ABX203.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ABX203.

Explore the full profile